Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
WuXi AppTec Co. (SS:603259) announced that its board has approved the distribution of a 2025 interim dividend, highlighting strong financial performance and confidence in future growth. The pharmaceutical and life sciences company will pay 3.50 yuan per 10 shares, with a total payout of 1 billion yuan scheduled for September 26, 2025.
Following the announcement, WuXi AppTec shares saw a positive market reaction. The company’s Hong Kong-listed stock rose 2.5% to HK$113.1, while its Shanghai-listed shares increased 0.7% to 109.55 yuan. Investors welcomed the dividend decision, viewing it as a sign of the company’s stable operations and optimistic outlook.
In its statement, WuXi AppTec emphasized that the payout reflects the board’s assessment of the firm’s operating results and overall financial strength. The move underscores the company’s strategy of rewarding shareholders while continuing to invest in long-term development across its global operations.
WuXi AppTec is a leading global provider of R&D and manufacturing services for the pharmaceutical, biotechnology, and medical device industries. With strong revenue streams and expanding international partnerships, the company remains positioned to benefit from rising demand in healthcare innovation.
The 2025 mid-year dividend marks another milestone for the company, reinforcing its track record of consistent shareholder returns. Market analysts noted that such decisions not only boost investor confidence but also support the stock’s long-term value in both Shanghai and Hong Kong markets.
By aligning its dividend strategy with solid financial results and a positive business outlook, WuXi AppTec continues to strengthen its reputation as a reliable growth-driven enterprise in China’s healthcare sector.
